Receptor binding studies of 5,14-O-dimethyloxymorphone (14-methoxymetopon) in brain membranes have established its high affinity for -binding sites, but its analgesic potency far exceeds the modest increase in binding affinity relative to other opioids. The current study has established the selectivity of -ol]-enkephalin (DAMGO) showed similar efficacies, as determined by maximal stimulation, but 14-methoxymetopon was up to 65-fold more potent than DAMGO. The greatest difference was seen with mMOR-1E and the least with mMOR-1C, which displayed only a 10-fold difference. These potency differences in the stimulation of [ 35 S]GTP␥S binding far exceeded the differences in binding affinity. The differences between 14-methoxymetopon and DAMGO remained after normalizing the potency shifts based upon receptor binding affinities and varied from 1.2-fold with mMOR-1C to 21-fold for mMOR-1 and 42-fold with mMOR-1F.
H]14-methoxymetopon for sites in calf striatal membranes and for a number of full-length splice variants of the cloned murine -opioid receptor 1 (mMOR-1) in transfected cell lines. The binding affinity of -ol]-enkephalin (DAMGO) showed similar efficacies, as determined by maximal stimulation, but 14-methoxymetopon was up to 65-fold more potent than DAMGO. The greatest difference was seen with mMOR-1E and the least with mMOR-1C, which displayed only a 10-fold difference. These potency differences in the stimulation of [ 35 S]GTP␥S binding far exceeded the differences in binding affinity. The differences between 14-methoxymetopon and DAMGO remained after normalizing the potency shifts based upon receptor binding affinities and varied from 1.2-fold with mMOR-1C to 21-fold for mMOR-1 and 42-fold with mMOR-1F. Thus, 14-methoxymetopon is a potent agonist against all of the mMOR-1 splice variants, but its potency ranged widely despite similar binding affinities for most of the variants and may give insight into its unusual pharmacological profile.
5,14-O-Dimethyloxymorphone (14-methoxymetopon) is a highly potent and selective -opiate agonist (Schmidhammer et al., 1990; Fü rst et al., 1993; Freye et al., 2000; Zernig et al., 2000; King et al., 2003; Bileviciute-Ljungar et al., 2006 ) with a unique pharmacology and extraordinary analgesic potency that sets it apart from traditional agonists. Despite its high analgesic potency, it displays little respiratory depression, bradycardia, or sedation compared with sufentanil. It decreases gastrointestinal transit far less than morphine and reportedly develops lower levels of tolerance and physical dependence and a diminished propensity to cause convulsions in mice. Supraspinal 14-methoxymetopon analgesia is antagonized by 3-O-methylnaltrexone at a dose that antagonizes both heroin and MG6, but not morphine (King et al., 2003) . Antisense mapping of MOR-1 also distinguishes 14-methoxymetopon from other opioids, with 14-methoxymetopon analgesia blocked by MOR-1 antisense probes against exons 1, 2, and 8, a pattern, however, different from that of either morphine or M6G (King et al., 2003) . Yet, the selectivity of 14-methoxymetopon for -opioid receptors is well established, based on receptor binding experiments and its sensitivity in vivo to -selective opioid antagonists, such as ␤-funaltrexamine and naloxonazine, but not or ␦ antagonists.
Early studies of multiple -opioid receptors used the antagonists naloxonazine and naloxazone to selectively block a -binding subtype and then define the pharmacological con-sequences of this blockade (Pasternak et al., 1980a,b; Wolozin and Pasternak, 1981) . In these early studies, naloxonazine selectively blocked morphine analgesia without interfering with respiratory depression or gastrointestinal transit, raising the possibility of distinct receptor mechanisms for these actions (Hahn et al., 1982; Ling et al., 1983 Ling et al., , 1984 Ling et al., , 1985 Lutz et al., 1984; Heyman et al., 1988; Paul and Pasternak, 1988) . This dissociation between analgesia and both respiratory depression and gastrointestinal inhibition is similar to the pharmacology reported with 14-methoxymetopon.
Since the initial descriptions of the cloning of MOR-1 (Chen et al., 1993; Eppler et al., 1993; Thompson et al., 1993; Wang et al., 1993) , a large number of MOR-1 splice variants have been isolated from mice (Pan et al., 1999 (Pan et al., , 2000 (Pan et al., , 2001 (Pan et al., , 2005b , rats (Zimprich et al., 1994; Pasternak et al., 2004) , and humans (Bare et al., 1994; Pan et al., 2003 Pan et al., , 2005a . The fulllength variants all contain identical binding pockets that are defined by exons 1, 2, and 3 and differ only at the tip of the C terminus. Thus, it was not surprising that all of the fulllength variants displayed high selectivity and similar affinities in binding affinity among the MOR-1 variants for a series of ligands. However, the small changes in the C terminus influenced both efficacy and potency functionally of a series of opioids, as illustrated by their different rank order potencies and efficacies among the splice variants (Bolan et al., 2004) . Therefore, we explored the ability of 14-methoxymetopon to bind to and activate MOR-1 splice variants.
Materials and Methods
[ 3 H]14-Methoxymetopon (15.9 Ci/mmol) was prepared as described previously (Spetea et al., 2001 (Schmidhammer et al., 1990) . All other opioids were obtained from the Research Technology Branch of the National Institute of Drug Abuse (Bethesda, MD). GDP sodium salt and peptidase inhibitor cocktail reagents (bestatin, leupeptin, pepstatin A, and aprotinin) were purchased from Sigma-Aldrich (St. Louis, MO).
Membranes were prepared from fresh tissue, with the exception of guinea pig cerebellum, which was obtained frozen (Harlan Bioproducts for Science Inc., Indianapolis, IN). Cell membrane preparations from CHO cells stably transfected with MOR-1 splice variants were obtained as described previously (Pan et al., 1999 (Pan et al., , 2000 (Pan et al., , 2001 . In brief, tissue or cell pellets were homogenized in 50 volumes of Tris buffer (50 mM Tris, pH 7.4, at 25°C) containing 10 M phenylmethylsulfonyl fluoride, 100 mM NaCl, and 1 mM K ϩ EDTA. The homogenate was incubated for 15 min at 25°C and centrifuged at 49,000g for 45 min. The pellet was resuspended in 0.32 M sucrose and frozen at Ϫ70°C until use. Saturation binding assays used varying concentrations of radioligands, whereas competition assays used a fixed amount of 35 S]GTP␥S, 1 g/ml peptidase inhibitor cocktail, and varying concentrations of unlabeled ligand in 1 ml of 50 mM Tris buffer, pH 7.4, containing 0.2 mM EGTA, 100 mM NaCl, and 3 mM MgCl 2 for 60 min at 30°C, as described previously (Bolan et al., 2004) . Unlabeled 100 M GTP␥S in the absence of ligand was used as an internal control to assess nonspecific binding. The reaction was terminated by rapid filtration over glass fiber filters using a Brandel cell harvester and subjected to liquid scintillation counting. Individual data points were tested in triplicate, and each assay was repeated at least three times. Results are presented as the maximal stimulation over 10 M DAMGO, normalized to 100%.
Results

General Characterization of [
3 H]14-Methoxymetopon Binding. 14-Methoxymetopon is a unique opioid. Competition binding studies have documented its high affinity for -binding sites, but even this affinity does not explain its exceedingly high potency as an analgesic. We therefore First, we established the binding assay in calf striatal membranes. Binding was temperature-dependent, with levels at 0°C approximately one-half those seen at 25°C (data not shown). Although binding increased further at 37°C, we chose 25°C to facilitate comparisons with the literature. Binding approached equilibrium by 150 min and remained stable for up to 3 h (Fig. 1A) . It was linear with tissue up to 20 mg wet weight ( Fig. 1C) and was optimal at pH 7 (Fig. 1D) . Saturation studies showed that [ 3 H]14-methoxymetopon labeled sites in the calf striatal membranes with high affinity (K D of 1 nM) (Fig. 2) . The linear Scatchard plot (inset) implies a similar affinity of all of the labeled sites, which was further supported by the linear semilog dissociation curve (Fig. 1B) .
[ 3 H]14-Methoxymetopon binding displayed agonist characteristics. Divalent cations enhance radiolabeled agonist binding , whereas sodium ions decrease it (Pert et al., 1973) . We saw a similar effect with [ 3 H]14-methoxymetopon binding (Fig. 3) . Sodium chloride lowered binding by approximately 75% at 100 mM, a result similar to other 3 H-opioid agonists. Conversely, magnesium increased binding and was used in subsequent assays. Radiolabeled opioid agonist binding is sensitive to GTP and its stable analogs Snyder, 1978, 1980; Childers et al., 1979) . The stable GTP analog Gpp(NH)p decreased [ 3 H]14-methoxymetopon binding in a dose-dependent manner (Fig.   3B ). The inclusion of sodium chloride potentiated this decrease, as shown previously for other radiolabeled opioid agonists.
The distribution of binding within calf brain was similar to that seen previously with other -opioid ligands, with highest levels in the striatum, followed by lower levels in the periaqueductal gray, thalamus, frontal cortex, and brain stem (Fig. 4) .
Competition studies in striatal membranes confirmed the selectivity of [ 3 H]14-methoxymetopon for sites. All of the opioids competed binding in a monophasic manner (Fig. 5) (Table  2) . Since the binding of the radioligands for a specific variant 3 H]14-methoxymetopon binding in calf striatal membranes. Binding was determined at the indicated concentration of radioligands. Results were also assessed using the Scatchard transformation (inset). This a representative experiment that has been replicated three times. The K D and the B max values for the three determinations are presented in Table 2 . 3 H]14-methoxymetopon raised the possibility that 14-methoxymetopon may be labeling both agonist and antagonist receptor conformations.
Stimulation of GTP␥S Binding in MOR-1 Variants. Although 14-methoxymetopon has a slightly higher affinity than DAMGO in receptor binding studies, these differences cannot explain its strikingly higher analgesic potency. Therefore, we compared 14-methoxymetopon and DAMGO functionally by examining their ability to stimulate [
35 S]GTP␥S binding in CHO cell lines expressing the variants ( Fig. 6 ; Table 3 ). Both 14-methoxymetopon and DAMGO maximally stimulated [
35 S]GTP␥S binding to a similar extent within each variant, suggesting that the two drugs had comparable efficacies. However, their potencies, as defined by EC 50 values, differed markedly (Table 3 ). 14-Methoxymetopon was 10-to 65-fold more active than DAMGO on the basis of EC 50 values. However, a portion of this difference may reflect the greater receptor occupancy at a given concentration of 14-methoxymetopon due to its higher binding affinity. Therefore, the data were normalized to account for the differences in binding site affinity by examining the EC 50 /K D ratio, which should provide an indication of the intrinsic activity of at ASPET Journals on May 14, 2017 jpet.aspetjournals.org the compound. Taking the binding affinity differences into consideration, the differences between the two drugs were lower, but still present. Indeed, there was little difference between the drugs for MOR-1C and only a modest difference for MOR-1D. However, we continued to see a 42-fold difference between the drugs for MOR-1F and a 21-fold difference with MOR-1 itself.
Discussion
[ 3 H]14-Methoxymetopon is a highly selective -opiate agonist with an analgesic potency well more than 100-fold that of morphine (Fü rst et al., 1993; Freye et al., 2000; Zernig et al., 2000; King et al., 2003) . Although radioligand binding studies confirm the selectivity of the ligand, they do not explain its extraordinary analgesic potency in vivo, which far exceeds its higher affinity for the receptors. Other aspects of its pharmacological profile also illustrate unusual characteristics, with ceiling effects on a number of other opioid actions, including respiratory depression and the inhibition of gastrointestinal transit (Freye et al., 2000; King et al., 2003) . Thus, this compound is quite unique. One possible explanation for this difference between the analgesic and other actions of 14-methoxymetopon may involve the concept of multiple -opioid receptors, as first formally proposed 25 years ago (Wolozin and Pasternak, 1981) . This proposal was initially based upon studies with naloxazone and naloxonazine, which selectively blocked morphine analgesia without interfering with respiratory depression or gastrointestinal transit (Hahn et al., 1982; Ling et al., 1983 Ling et al., , 1984 Ling et al., , 1985 Lutz et al., 1984; Heyman et al., 1988; Paul and Pasternak, 1988) . This dissociation between analgesia and both respiratory depression and gastrointestinal inhibition is similar to the pharmacology reported with 14-methoxymetopon.
Binding was first carried out in calf brain membranes to validate the assay conditions and to create a detailed binding profile of 14-methoxymetopon, controlling for tissue linearity, pH, temperature, and ions. Binding criteria were similar to other 3 H-opioid ligands. [ 3 H]14-Methoxymetopon labeled calf striatal membranes with a K D of 0.99 nM and a distribution similar to that observed previously with other radioligands. The binding responded to temperature, divalent cations, guanine nucleotides, and sodium ions as reported previously for 3 H-opioid agonists (Pert et al., 1973; Creese et al., 1975; Pasternak et al., 1975; Childers and Snyder, 1978) . Saturation studies revealed linear Scatchard plots in the brain membranes. However, with a multitude of MOR-1 variants present in the tissue, the radioligand was clearly labeling more than one receptor. Thus, the linear plot implies a similar affinity of the radioligand for the sites labeled. This is supported by the linear semilog dissociation curve. These observations were similar to those previously reported in rat brain, which also showed high affinity for the ligand (K D of 0.43 nM) and a linear Scatchard plot (Spetea et al., 2003a) .
In rat brain, [ 3 H]methoxymetopon reportedly labels only sites (Spetea et al., 2003) . Our results in calf brain were similar, with all of the binding effectively competed by -selective ligands. The competition curves were monophasic and showed no evidence of a binding site that was insensitive to traditional opioids. In addition, the K i values were similar to those determined in the same tissue preparations with (p Ͻ 0.001). We considered the possibility that [
3 H]14-methoxymetopon was labeling a unique site unrelated to the receptor, but we feel that this is unlikely since all of the binding was sensitive to opioids. Radiolabeled antagonists oftentimes label more sites since they bind both agonist and antagonist receptor conformations, unlike agonists that typically label only the agonist conformation. The similar [ 3 H]14-methoxymetopon and [
3 H]naloxone B max levels raised the interesting possibility that 14-methoxymetopon may label both conformations, a possibility supported by the binding studies with the expressed variants (see below). This would set the drug apart from traditional agonists and might potentially help explain its unusual potency.
To more fully explore the mechanisms of 14-methoxymetopon, we examined its binding and functional activity in CHO cells expressing a series of full-length MOR-1 splice variants. [ 3 H]14-Methoxymetopon displayed similar high affinities for all of the variants, except for MOR-1F, which was significantly lower (p Ͻ 0.001). Since MOR-1F has the identical transmembrane domains as the other variants, the difference in affinity can only be due to the changes in amino acids at the C terminus.
The Functionally, 14-methoxymetopon was a full agonist at each splice variant, with the maximal stimulation of [ 35 S]GTP␥S binding, a measure of efficacy, virtually the same as DAMGO. However, the relatively potencies of the two agents varied far more than would be anticipated based upon binding affinities alone. The greatest differences were seen with MOR-1 and MOR-1E, where 14-methoxymetopon was over 50-fold more potent. To provide a comparison that takes into account the differences in their affinities in binding studies, we also compared the two agents using the ratio of the EC 50 and the K i . The ratio should provide an indication of the relative potencies of the drugs at similar receptor occupancies, an indication of their relative intrinsic activities. As anticipated, the differences between the two drugs within a variant narrowed when using the ratios, but still varied markedly from variant to variant. Although the two drugs ratios showed little difference for MOR-1C and a very modest difference for MOR-1D, there was a 40-fold difference for MOR-1F. These observations illustrate that the intrinsic activity of 14-methoxymetopon differs from variant to variant as well as from that of DAMGO. These enhanced potencies, which were independent from efficacy, are consistent with the extremely high analgesic activity of the drug.
The reasons for these functional differences are not clear. The ability of 14-methoxymetopon to label both agonist and antagonist conformations of the receptor may help explain far greater potency than DAMGO in many of the assays. However, this does not explain the variability among the splice variants for 14-methoxymetopon itself. These differences are not unique to this agent. Prior studies revealed similar differences in the functional activation of the variants by a number of opioids in all species examined (Pan et al., 2003 (Pan et al., , 2005a Bolan et al., 2004; Pasternak et al., 2004) . The only structural differences among the full-length splice variants involve the amino acids at the tip of the C terminus. In MOR-1, exon 4 encodes 12 amino acids (LENLEAETAPLP), which are replaced in the other variants. These 12 amino acids are replaced by a wide range of sequences, from only two in MOR-1B5 to 58 in MOR-1F. How these differences at the C terminus may influence the activation of the receptor is still under investigation. Evidence suggests that the different sequences can influence the proteins associated with the receptor in the membrane and even which G protein ␣ subunit that associates with the receptor (Premkumar, Pan, and Pasternak, unpublished observations). However, the mechanism through which these sequences alter these associations has not been determined.
In conclusion, 14-methoxymetopon is a very unusual opioid analgesic. In vivo, its analgesic activity far exceeds that of morphine and most other opioids, despite very limited differences in binding affinities. The current study demonstrates the high binding affinity of 14-methoxymetopon for a series of mouse MOR-1 variants and an unexpectedly potent activation of [ 35 S]GTP␥S binding. However, the enhanced relative functional potency compared with DAMGO varied considerably from one variant to another, suggesting that the intrinsic activity of 14-methoxymetopon was dependent upon the variant being examined. This may help explain its unusual pharmacological profile.
